Abivax SA (NASDAQ:ABVX) reported mixed results for the first half of the year on Monday.

The company posted losses of $2.43 per share, compared to the analyst consensus estimate of losses of $1.08 per share. The company reported sales of $2.959 million which beat the analyst consensus estimate of $1.860 million.

Abivax shares fell 0.1% to $103.41 in pre-market trading.

These analysts made changes to their price targets on Abivax following earnings announcement.

• Wedbush analyst David Nierengarten maintained the stock with a Neutral and lowered the price target from $140 to $118.
• Truist Securities analyst Gregory Renza maintained the stock with a Buy and lowered the price target from $155 to $151.

Considering buying ABVX stock? Here’s what analysts think:

Photo via Shutterstock